Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triac Trial II of tiratricol in infants and young boys with MCT8 deficiency
NL-OMON52600Phase 2Recruiting
- Sponsor
- Egetis Therapeutics
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiratricol in Allan-Herndon-Dudley syndrome (AHDS), sponsored by Egetis Therapeutics. Primary endpoints: GMFM-88 total score at week 96, BSID-III Gross Motor Skill Domain at week 96 and 2 more. Started Jan 2021; status: recruiting.
02
Drugs
tiratricol
03
Conditions
Allan-Herndon-Dudley syndrome (AHDS)
Beyond the preview
Go deeper on NL-OMON52600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52600.